Taladegib

N/A

Report date: 2026/04/08 15:32:29
NME

Base Information

Drug NameTaladegib
Drug Alias Name他拉地吉Taladegibum他拉德吉Taladegib HydrochlorideLY-2940680 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSmoothened receptor antagonists
TargetsSmoothened receptor
Therapy Area/IndicationsSolid tumoursIdiopathic Pulmonary FibrosisNeoplasm Metastasis +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEndeavor Biomedicines Inc
Inactive CompaniesEli Lilly And Company
Active IndicationsIdiopathic Pulmonary Fibrosis
Inactive IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[10] 

Other Information

ATC CodeN/A
Related LinksKEGG